Evaluation of a Combined Near Infrared Spectroscopy (NIRS) and Intravascular Ultrasound (IVUS) Catheter for Detection of Lipid Rich Plaque


The purpose of this study is to learn more about lipid rich plaque using Near Infrared Spectroscopy (NIRS)/Intravascular Ultrasound (IVUS) imaging in patients who have had coronary artery stenting and Optical coherence tomography (OCT) imaging.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Diagnostic
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 2012

Detailed Description

The aims of this study are to: 1. Test the ability of the new NIRS IVUS system to detect lipid pool 2. Evaluate the accuracy of the NIRS IVUS system for localization of lipide rich plaque: superficial vs deep 3. Improve diagnostic accuracy of OCT for detection of lipid using information from NIRS IVUS


  • Device: InfraReDx Lipiscan IVUS
    • Near Infrared Spectroscopy/Intravascular Ultrasound will be performed following OCT imaging.

Arms, Groups and Cohorts

  • Experimental: Coronary stenting with OCT, NIRS/IVUS
    • All subjects will have Near Infrared Spectroscopy/Intravascular Ultrasound Imaging performed.

Clinical Trial Outcome Measures

Primary Measures

  • Detection of Lipid Rich Plaque by Near Infrared Spectroscopy (NIRS) Intravascular Ultrasound (IVUS)
    • Time Frame: Measured one point in time during cardiac catheterization
    • Subjects are presenting for their clinically-indicated cardiac catheterization. NIRS/IVUS imaging will be done at the time of catheterization.

Secondary Measures

  • Differences in NIRS Parameters Between Deep and Superficial Lipid Assessed by Optical Coherence Tomography (OCT).
    • Time Frame: Measured at the time of cardiac catheterization
    • Subjects are presenting for their clinically-indicated cardiac catheterization. NIRS/IVUS imaging will be done at the time of catheterization. Plaques were divided depending on depth of lipid by OCT (cut off value 130 um).

Participating in This Clinical Trial

Inclusion Criteria

Patient Characteristics 1. Males and non-pregnant females > 18 and < 79 years of age 2. Patients referred for diagnostic coronary angiography who are found to have lesions in native coronary arteries which will be treated by percutaneous coronary intervention (PCI) (or patients with known coronary lesions who are referred for planned PCI) 3. Able to give written informed consent Lesion Characteristics 1. Lesion in native coronary artery 2. Angiographic stenosis > 50% 3. Reference vessel diameter 2.5 mm – 4.0 mm by visual estimation 4. Subjects who have successful PCI and OCT General Exclusion Criteria 1. Subjects who are unable or unwilling to sign the informed consent form 2. Subjects with serious co-morbid conditions that in judgment of the investigator preclude inclusion in this study (such as terminal cancer, life expectancy < 6 months, Liver Function Tests (LFTs) > 3 times Upper Limit of Normal (ULN), or post-transplant) 3. Subjects with New York Heart Association (NYHA) class III or IV heart failure or known left ventricular ejection fraction < 30% 4. Subjects who have experienced an ST-elevation myocardial infarction (STEMI) within 72 hours prior to the procedure 5. Subjects with hemodynamic or electrical instability (including shock) 6. Subjects diagnosed with severe, non-catheter-related coronary artery spasm 7. Subjects who are or may be pregnant 8. Subjects with known allergies to contrast media 9. Subjects with renal failure as defined by estimated Glomerular Filtration Rate (eGFR) < 60. 10. History of Transient Ischemic Attack (TIA) or stroke < 6 months Lesion Specific Exclusion Criteria These exclusion criteria apply to the target lesion to be imaged by NIRS IVUS. 1. Lesion located in the left main coronary artery 2. Lesions that are heavily calcified 3. Lesions where OCT cannot be performed due to technical difficulties 4. Other lesions that the investigator deems inappropriate for the procedure such as lesions with excessive tortuosity, presence of thrombus, low flow by TIMI grade.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 79 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Massachusetts General Hospital
  • Collaborator
    • Infraredx
  • Provider of Information About this Clinical Study
    • Principal Investigator: Ik-Kyung Jang, MD, PhD, Professor of Medicine – Massachusetts General Hospital
  • Overall Official(s)
    • Ik-Kyung Jang, MD, PhD, Principal Investigator, Massachusetts General Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.